Effectiveness and safety of narlaprevir in real clinical practice of chronic hepatitis C

Effectiveness and safety of narlaprevir in real clinical practice of chronic hepatitis C

Objective: to analyze the efficacy and safety of using direct antiviral action drug narlaprevir/ritonavir in combination with the prolonged alpha-interferon and ribavirin drugs in the conditions of day-time hospitals of St. Petersburg and. Novgorod.Materials and methods: The study included. 35 patie...

Full description

Saved in:

Bibliographic Details
Main Authors:	V. V. Basina, S. E. Kalach, N. V. Tyurenkova, M. E. Semenova, E. Yu. Yushina, E. G. Gordievskaya, R. A. Ganchenko, Е. V. Esaulenko
Format:	Article
Language:	Russian
Published:	Journal Infectology 2019-12-01
Series:	Журнал инфектологии
Subjects:	antiviral therapy narlaprevir chronic hepatitis c 1 genotype
Online Access:	https://journal.niidi.ru/jofin/article/view/963
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

PROTEASE INHIBITOR NARLAPREVIR IN THERAPY OF HEPATITIS C VIRUS GENOTYPE 1 INFECTION IN TREATMENT-NAÏVE PATIENTS WITHOUT CIRRHOSIS: PHARMACOECONOMIC EVALUATION
by: A. V. Rudakova, et al.
Published: (2017-04-01)

Cost-effectiveness of narlaprevir in the chronic hepatitis C (genotype 1) therapy in treatment-naïve patients and relapsers
by: D. A. Gusev, et al.
Published: (2016-11-01)

Сost-effectiveness of the second wave of protease inhibitors in the treatment of chronic hepatitis C (genotype 1) in patients not previously treated with antiviral drugs, and for relapsed disease
by: A. V. Rudakova, et al.
Published: (2016-04-01)

Liver cirrhosis as a result of chronic hepatitis C
by: A. A. Sukhoruk, et al.
Published: (2014-09-01)

Efficiency of Antiviral Therapy for Recurrence of Chronic Hepatitis C in Patients Undergoing Liver Transplantation
by: A. A. Sukhoruk, et al.
Published: (2014-09-01)

Efficacy and safety of сepeginterferon alfa-2b in double treatment regimen (cepeginterferon alfa-2b and ribavirin) of antiviral therapy in patients with chronic hepatitis C genotypes 2 and 3. Experience of real clinical practice
by: A. I. Pavlov, et al.
Published: (2016-11-01)

RESULTS OF THE USE OF SOFOSBUVIR IN COMBINATION WITH LEDIPASVIR OR DACLATASVIR FOR CHRONIC HEPATITIS C TREATMENT IN THE REPUBLIC OF BELARUS
by: S. V. Zhavoronok, et al.
Published: (2018-10-01)

Cost-effectiveness of antiviral therapy in treatment-naive patients with chronic hepatitis C (genotype 1)
by: A. V. Rudakova, et al.
Published: (2017-06-01)

TREATMENT OF HEPATITIS C WITHOUT INTERFERON IN PATIENTS UNDERGOING LIVER TRANSPLANTATION
by: M. Sh. Khubutia, et al.
Published: (2015-10-01)

A cross-sectional study of real life data of HCV from Turkey south region
by: Bedia Mutay Suntur, et al.
Published: (2020-04-01)

Real-world effectiveness and safety of pan-genotypic antiviral therapy for chronic HCV-infection: data from three clinical centers in St. Petersburg
by: D. A. Gusev, et al.
Published: (2023-01-01)

The prognostic value of ferritinemia level in patients with chronic hepatitis C
by: N. C. Sargsyants, et al.
Published: (2013-07-01)

Genotypic Diversity of Hepatitis C Virus in Tuberculosis Patients in the Tomsk Region
by: K. A. Svirin, et al.
Published: (2025-03-01)

Efficacy of direct-acting antivirals in patients with hepatitis C virus-associated cryoglobulinemic vasculitis: Results of a long-term follow-up
by: S. V. Gavrisheva, et al.
Published: (2023-04-01)

Effectiveness and safety of sofosbuvir/velpatasvir in chronic hepatitis C virus infection of Bangladeshi children
by: Salahuddin Mahmud, et al.
Published: (2025-06-01)

Characteristics of Hepatitis C Epidemic Process in the Republic of Belarus
by: V. S. Vysotskaya, et al.
Published: (2021-01-01)

VIRAL HEPATITIS C – GLOBAL HEALTH PROBLEM
by: Kalina Terzieva, et al.
Published: (2025-02-01)

POSSIBILITIES OF HEPATITIS C ANTIVIRAL TREATMENT IN LIVER TRANSPLANT RECIPIENTS
by: V. E. Syutkin, et al.
Published: (2011-06-01)

Are there differences in efficacy and safety between local and imported direct-acting antiviral agents for hepatitis C in China?
by: Zhitao Wang, et al.
Published: (2025-07-01)

Cryoglobulinemia and hepatitis C virus
by: N. V. Dunaeva, et al.
Published: (2014-09-01)

Effectiveness and Safety of Direct-Acting Antivirals in the Treatment of Chronic Hepatitis C: A Real-life Study in Northeastern Brazil
by: Elodie Bomfim Hyppolito, et al.
Published: (2024-11-01)

CLINICAL AND MORPHOLOGICAL FEATURES OF CHRONIC HEPATITIS C IN YOUNG CHILDREN
by: S. V. Chuelov, et al.
Published: (2015-08-01)

Successful antiviral therapy for chronic hepatitis C in a patient after surgery for hepatocellular carcinoma (a clinical observation)
by: I. G. Nikitin, et al.
Published: (2018-08-01)

The use of telaprevir for the treatment of hepatitis C in patients undergoing liver transplantation (Literature review and clinical experience)
by: M. Sh. Khubutiya, et al.
Published: (2016-02-01)

Changes in Hepatitis C Virus Genotype Distribution in Diyarbakır from 2011 to 2020: The Impact of Migration and Epidemiological Trends
by: Esra Yenihal, et al.
Published: (2024-12-01)

Clinical and epidemiological characteristic of chronic hepatitis C in the republic of Tyva
by: A. A. Saryglar, et al.
Published: (2023-04-01)

Justification of the program therapy of acute hepatitis C
by: E. A. Mikhailova, et al.
Published: (2014-09-01)

Intercellular interactions and their role in fibrogenesis in chronic hepatitis C
by: I. A. Karabak, et al.
Published: (2022-05-01)

The efficacy and safety of double (cepeginterferon alfa-2b and ribavirin) and triple (simeprevir, cepeginterferon alfa 2b and ribavirin) treatment regimens in chronic hepatitis C patients. The experience of everyday clinical practice
by: N. P. Blokhina, et al.
Published: (2016-07-01)

Development of approaches to the evaluation of pharmacotherapy effectiveness for chronic hepatitis C
by: I. A. Narkevich, et al.
Published: (2024-02-01)

Liver CT Perfusion Imaging as a Non-Invasive Method for Assessing Hemodynamics of the Hepatic Parenchyma in Patients with Fibrosis and Cirrhosis as a Result of Chronic Viral Hepatitis C
by: G. A. Stashuk, et al.
Published: (2022-02-01)

B-cell non-Hodgkin's lymphoma in the patient with chronic hepatitis C and mixed cryoglobulinemia
by: V. S. Adonyeva, et al.
Published: (2015-03-01)

Treatment of hepatitis C in liver transplant recipients in the Moscow Center for Liver Transplantation within 10 years
by: M. Sh. Khubutia, et al.
Published: (2016-01-01)

Hepatitis C Virus Resistance-Associated Substitutions in Mexico
by: Alexis Jose-Abrego, et al.
Published: (2025-01-01)

Efficacy of antiviral therapy in the treatment of severe forms of acute hepatitis B
by: E. V. Esaulenko, et al.
Published: (2016-02-01)

The incidence of chronic viral hepatitis and the analysis of the genetic diversity of hepatitis B and C viruses among the population of Khabarovsk city
by: Valeriya O. Kotova, et al.
Published: (2025-03-01)

Clinical and immunomorphological predictors of the adverse course of chronic hepatitis C
by: I. A. Karabak, et al.
Published: (2020-06-01)

Iron metabolism in chronic hepatitis C patients on antiviral treatment
by: K. V. Zhdanov, et al.
Published: (2014-09-01)

ETIOTROPIC THERAPY OF VIRAL HEPATITIS
by: S. B. Chuelov, et al.
Published: (2017-09-01)

Betaleukin in therapy of chronic hepatitis C
by: E. S. Romanova, et al.
Published: (2014-10-01)